Dr. Bauml Discusses Biomarkers in Head and Neck Cancer

Video

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

Both pembrolizumab (Keytruda) and nivolumab (Opdivo) are FDA approved for the treatment of patients with head and neck cancer, says Bauml, and are being used in a biomarker-agnostic fashion. The benefit for nivolumab is higher for patients with PD-L1—positive disease.

The FDA granted accelerated approval to pembrolizumab in August 2016 based on the objective response rates (ORR) of the phase Ib KEYNOTE-012 study. The ORR with pembrolizumab was 16% (95% CI, 11%-22%), which included a complete response rate of 5%. Responses lasted for ≥6 months for 82% of patients.

The FDA approved nivolumab in November 2016 based on the CheckMate-141 study. The median overall survival with nivolumab was 7.5 months compared with 5.1 months with investigator’s choice (HR, 0.70; 95% CI, 0.52-0.92; P = .0101). The objective response rate (ORR) was 13.3% with nivolumab and 5.8% for investigator's choice.

According to Bauml, if agents are given in combination, better biomarkers are needed to determine which patients should receive it.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute